55-57-2

Usage

Uses

Used in Pharmaceutical Industry:
1-Phenylbiguanide Hydrochloride is used as a pharmacological agent for its cardiovascular effects. In anesthetized dogs, it has been observed to have a significant impact on the cardiovascular system, making it a potential candidate for the development of new drugs targeting cardiovascular conditions.
Used in Research Applications:
As a SR-3 agonist, 1-Phenylbiguanide Hydrochloride is used in research settings to study the effects and mechanisms of action of this receptor. Understanding the role of SR-3 in various physiological processes can lead to the development of targeted therapies for a range of conditions, including those related to the cardiovascular system.
Used in Drug Development:
1-PHENYLBIGUANIDE HYDROCHLORIDE's agonistic properties towards the SR-3 receptor make it a valuable tool in the development of new drugs. Researchers can use 1-Phenylbiguanide Hydrochloride to design and test novel compounds that may have improved efficacy and selectivity for the SR-3 receptor, potentially leading to more effective treatments for various diseases and conditions.

Safety Profile

Poison by intraperitoneal route. Moderately toxic by ingestion.When heated to decomposition it emits very toxic fumes of HCl and NOx.

InChI:InChI=1/C8H11N5.ClH/c9-7(10)13-8(11)12-6-4-2-1-3-5-6;/h1-5H,(H6,9,10,11,12,13);1H

Upstream product

• 142-04-1 aniline hydrochloride 
• 127099-85-8 N-Cyanoguanidine 
• 62-53-3 aniline 
• 127099-85-8 dicyandiamide 

Downstream Products

• 100139-27-3 6-(1-methoxy-ethyl)-N²-phenyl-[1,3,5]triazine-2,4-diyldiamine 
• 30355-60-3 6-chloromethyl-N-phenyl-[1,3,5]triazine-2,4-diamine 
• 107412-68-0 2-Amino-4-phenylamino-6-(2-pyridyl)-1,3,5-triazine 
• 7426-35-9 2-amino-4-anilino-6-methyl-1,3,5-triazine 
• 86176-95-6 N-(4-Hydroxy-6-trifluoromethyl-pyrimidin-2-yl)-N'-phenyl-guanidine 
• 114811-92-6 4-[2-(4-Amino-6-phenylamino-[1,3,5]triazin-2-yl)-ethyl]-2,6-di-tert-butyl-phenol 
• 537-17-7 W 1191-2 
• 86177-14-2 N-[4-(3-Ethylaminomethyl-4-methoxy-phenylamino)-6-trifluoromethyl-pyrimidin-2-yl]-N'-phenyl-guanidine 
• 86177-12-0 N-[4-(3-Diethylaminomethyl-4-hydroxy-phenylamino)-6-trifluoromethyl-pyrimidin-2-yl]-N'-phenyl-guanidine 
• 86177-15-3 N-[4-(3-Diethylaminomethyl-4-methoxy-phenylamino)-6-trifluoromethyl-pyrimidin-2-yl]-N'-phenyl-guanidine 
• 86177-13-1 N-{4-[4-Hydroxy-3-(4-methyl-piperazin-1-ylmethyl)-phenylamino]-6-trifluoromethyl-pyrimidin-2-yl}-N'-phenyl-guanidine 
• 86177-16-4 N-{4-[4-Methoxy-3-(4-methyl-piperazin-1-ylmethyl)-phenylamino]-6-trifluoromethyl-pyrimidin-2-yl}-N'-phenyl-guanidine 

Relevant academic research and scientific papers

Structural Insights into the Development of Cycloguanil Derivatives as Trypanosoma brucei Pteridine-Reductase-1 Inhibitors

Cycloguanil is a known dihydrofolate-reductase (DHFR) inhibitor, but there is no evidence of its activity on pteridine reductase (PTR), the main metabolic bypass to DHFR inhibition in trypanosomatid parasites. Here, we provide experimental evidence of cycloguanil as an inhibitor of Trypanosoma brucei PTR1 (TbPTR1). A small library of cycloguanil derivatives was developed, resulting in 1 and 2a having IC50 values of 692 and 186 nM, respectively, toward TbPTR1. Structural analysis revealed that the increased potency of 1 and 2a is due to the combined contributions of hydrophobic interactions, H-bonds, and halogen bonds. Moreover, in vitro cell-growth-inhibition tests indicated that 2a is also effective on T. brucei. The simultaneous inhibition of DHFR and PTR1 activity in T. brucei is a promising new strategy for the treatment of human African trypanosomiasis. For this purpose, 1,6-dihydrotriazines represent new molecular tools to develop potent dual PTR and DHFR inhibitors.

BIGUANIDE COMPOUND AND USE THEREOF

The present invention relates to a guanidine compound and a use thereof, and more specifically, to a guanidine derivative showing excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence; a preparation method thereof; and a pharmaceutical composition containing the same as an active ingredient. Compared to existing drugs, the guanidine derivative according to the present invention shows excellent effects of inhibiting cancer cell proliferation, cancer metastasis, and cancer recurrence even with small doses, and may thus be effectively used in preventing or treating various cancers such as uterine cancer, breast cancer, stomach cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, liver cancer, etc., inhibiting cancer cell proliferation and cancer metastasis.

Synthesis and antiviral activity of benzimidazolyl-and triazolyl-1,3,5- triazines

A novel series of 1,3,5-triazine analogs was successfully synthesized through conjugation with benzimidazole or 1,2,4-triazole derivatives via a methylenethio linker. The new analogs were in vitro evaluated against HSV-1 in Vero cells; among these analogs, two compounds exhibited good effect in inhibiting HSV-1 replication (for compound 5p: EC50 = 3.5 μg/ml, SI = 358; for compound 5r: EC50 = 5.0 μg/ml, SI = 300) in comparison to acyclovir. Springer Science+Business Media, LLC 2011.